About PENTAPHARM
PENTAPHARM is a Healthcare company based in Aesch (Switzerland) founded in 1948. It supplies active ingredients, reagents, and enzymes for diagnostics and pharmaceuticals sectors. It operates on a B2B model. The company has 38 employees. Its Indian entity Penta Pharma Private Limited reported revenue of ā¹10.84 Cr. PENTAPHARM offers products and services including Aprotinin, DefibraseĀ®, Chromogenic Substrates, Fluorogenic Substrates, and ReptilaseĀ®. Its focus areas include Diagnostics, In Vitro Diagnostics, Reagents and Kits and Pharmaceuticals.
Company details
Pentapharm is a supplier of innovative active ingredients and reagents for the pharmaceutical and diagnostic industries. They develop and provide products like chromogenic substrates, inhibitors, and enzymes, serving global markets through reliable distribution. Based primarily in Switzerland with additional offices in the USA and China, they focus on quality assurance and regulatory compliance to meet industry needs.
- Headquarters Aesch, Switzerland
- Employees 38
- SectorsHealthcare
- Website pentapharm.com
- Legal Name Penta Pharma Private Limited
- Date of Incorporation 17 Oct, 1991
- Jurisdiction Kanpur Dehat, Uttar Pradesh, India
- Annual Revenue₹10.84 Cr
FY 2023 · 0% YoY
- Net Profit₹13 Lakh
FY 2023 · 1% margin
- EBITDA-₹5.42 Cr
FY 2023 · -50% margin
- Employee Count38
Associated legal entities of PENTAPHARM
PENTAPHARM operates through Penta Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Penta Pharma Private Limited CIN U24231UP1991PTC013617 | Active | 17 Oct 1991 | Kanpur Dehat, Uttar Pradesh | ₹10.8 Cr | 38 | 3 | View details |
Products & Services of PENTAPHARM
PENTAPHARM offers a comprehensive portfolio of products and services, including Aprotinin, Defibrase®, Chromogenic Substrates, Fluorogenic Substrates, and Reptilase®.
Protease inhibitor used in pharmaceutical and therapeutic applications
Batroxobin enzyme for blood coagulation treatments
Substrates for detecting enzymatic activities in tests
Substrates for fluorescent assays in diagnostics
Haemocoagulase for blood clotting diagnostics
Board of directors of Penta Pharma Private Limited (PENTAPHARM)
Penta Pharma Private Limited is the primary company behind PENTAPHARM. The board of Penta Pharma Private Limited currently have 3 directors; the longest-serving is Rajeev Kumar Maheshwari, appointed in 1991. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rajeev Kumar Maheshwari DIN 01798783 | Managing Director | 17 Oct 1991 | 35 yrs | Penta Pharma Private Limited |
| Shikhar Maheshwari DIN 08086818 | Director | 20 Feb 2018 | 8 yrs 8 mo | Penta Pharma Private Limited |
| Padma Maheshwari DIN 08086822 | Director | 20 Feb 2018 | 8 yrs 8 mo | Penta Pharma Private Limited |
Financials of PENTAPHARM
Figures of Penta Pharma Private Limited, the primary company behind PENTAPHARM, for FY 2023. Revenue was ₹10.84 Cr (0% year on year). Net profit was ₹13 Lakh (1% margin). EBITDA was -₹5.42 Cr (-50% margin). Revenue has grown at a compounded annual rate of -1% over three years and +51% over five years.
- ₹10.84 CrRevenue · FY 2023 · 0% YoY
- ₹13 LakhNet profit · 1% margin
- -₹5.42 CrEBITDA · -50% margin
- ₹1.99 CrPaid-up capital
- 38Employees (provident fund records)
- -1%Revenue CAGR, 3 years
- +51%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Penta Pharma Private Limited are on its company page.
Detailed financial statements for PENTAPHARM
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Top companies in Diagnostics Laboratories
10 companies that operate in the same segment as PENTAPHARM (Diagnostics Laboratories), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Diagnostic testing centers for pathology and health screenings are operated. | 1996 | Mumbai, Maharashtra, India | USD 63.59 M | USD 88.36 M | 1,950 | |
Chain of pathology and radiology labs | 1949 | Gurugram, Haryana, India | USD 13.9 M | USD 294.49 M | 5,310 | |
Home-based diagnostic tests are booked via an online platform. | 2018 | Noida, Uttar Pradesh, India | USD 116.42 M | USD 41.86 M | 2,308 | |
Pathology, radiology, wellness and clinical research services | 1995 | Mumbai, Maharashtra, India | – | – | – | |
Diagnostic centers are operated as a nationwide chain. | 1981 | Mumbai, Maharashtra, India | USD 228.2 M | USD 175.43 M | 5,180 | |
Radiology centers are operated as a nationwide chain. | 1984 | Los Angeles, California, United States | – | USD 2.04 B | 8,550 | |
DNA sequencing, bioinformatics, and multiomics services are provided. | 2013 | Bengaluru, Karnataka, India | USD 264.5 M | USD 29.55 M | 883 | |
Chain of radiology centers | 2015 | Jacksonville, United States | – | USD 749.63 M | 5,486 | |
At-home diagnostic tests are booked and collected by phlebotomists. | 2020 | Bengaluru, Karnataka, India | USD 77.12 M | USD 3.34 M | 719 | |
Biomarker analysis and diagnostic tests are offered by the laboratory. | 2012 | Gurugram, Haryana, India | USD 17.26 M | USD 11.27 M | 496 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track ā from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PENTAPHARM
PENTAPHARM was founded in 1948.
PENTAPHARM is headquartered in Aesch, Switzerland. It is registered at Aesch, Basel-landschaft, Switzerland.
PENTAPHARM has 38 employees.
The primary company behind PENTAPHARM, Penta Pharma Private Limited, reported revenue of ā¹10.84 Cr for FY 2023, down 0% year on year.
Pentapharm is a supplier of innovative active ingredients and reagents for the pharmaceutical and diagnostic industries. They develop and provide products like chromogenic substrates, inhibitors, and enzymes, serving global markets through reliable distribution. Based primarily in Switzerland with additional offices in the USA and China, they focus on quality assurance and regulatory compliance to meet industry needs.
PENTAPHARM offers Aprotinin, DefibraseĀ®, Chromogenic Substrates, Fluorogenic Substrates, and ReptilaseĀ®.
PENTAPHARM operates through Penta Pharma Private Limited.
The legal entities of PENTAPHARM currently have 3 directors, including Shikhar Maheshwari, Rajeev Kumar Maheshwari, Padma Maheshwari.